Morab-022 (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01357759 (ClinicalTrials.gov) | May 2013 | 18/5/2011 | Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects | A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Trial of MORAb-022 in Healthy Subjects and Subjects With Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: MORAb-022 | Morphotek | NULL | Completed | 18 Years | 75 Years | Both | 20 | Phase 1 | United States;Netherlands |